Cargando…
Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study
INTRODUCTION: MIJ821 is a novel N-methyl-D-aspartate (NMDA) receptor antagonist, with a potentially low rate of the psychotomimetic side effects that limit the therapeutic utility of ketamine in treatment-refractory depression (TRD). OBJECTIVES: To assess efficacy and safety of MIJ821. METHODS: Adul...
Autores principales: | Ghaemi, N., Sverdlov, A., Shelton, R., Litman, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471356/ http://dx.doi.org/10.1192/j.eurpsy.2021.897 |
Ejemplares similares
-
MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose)
por: Gomez‐Mancilla, Baltazar, et al.
Publicado: (2023) -
De griepprik: ‘Mij (ook nu) niet gezien?’
por: Berends, Nienke
Publicado: (2020) -
Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
por: Arnold, Leslie M, et al.
Publicado: (2020) -
147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
por: Pappas, Peter, et al.
Publicado: (2020) -
821. Positive Follow-Up Blood Culture in Candidemia and Ocular Involvement
por: Iqbal, Hamail, et al.
Publicado: (2023)